secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024446
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance
-----------------------------------------------------------------------------

- Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.
- Cash $290.4M at Sept 30, up from $208.4M at Dec 31, 2021, driven by ATM proceeds.
- MISSION Phase 2 lupus nephritis: ORR 64.7% at week 25, 88.2% at week 37; CRR 35.3% then 41.2%.
- FDA cleared IND for zetomipzomib in autoimmune hepatitis; PORTOLA Phase 2a trial to start.
- Preclinical KZR-540, an oral PD-1 expression blocker, presented at SITC on Nov 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/0000950170-22-024446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/kzr-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer